Table 1:
Baseline clinical characteristics of the study cohort
| Characteristic | AF | Control | P-value |
|---|---|---|---|
| Number | 50 | 50 | |
| Age, years | 66 (57.00, 71.25) | 55 (50.50, 57.50) | <0.001 |
| Male/female sex | 32/18 | 41/9 | 0.043 |
| Body mass index | 26.46 (23.79, 28.64) | 24.77 (22.79, 27.62) | 0.112 |
| HTN | 27 | 27 | |
| T2DM | 12 | 0 | |
| Total cholesterol | 4.13 ± 1.05 | 4.82 ± 0.96 | 0.001 |
| Triglyceride | 1.29 (1.02, 1.88) | 1.06 (0.77, 1.80) | 0.084 |
| LDL cholesterol | 2.45 (1.58, 2.93) | 2.3 (1.96, 2.86) | 0.872 |
| Fasting blood glucose | 4.95 (4.50, 5.83) | 5.12 (4.56, 5.55) | 0.883 |
| Creatinine | 68.5 (60.48, 79.35) | 70 (60, 89.5) | 0.533 |
| Uric acid | 321.5 (278, 389.75) | 333 (264.5, 384) | 0.927 |
| Total bilirubin | 14 (10.08, 19.5) | 14.7 (11.59, 19.75) | 0.431 |
| Glutamic-pyruvic transaminase | 19 (13.75, 28.5) | 19 (12, 25) | 0.185 |
| Drug use | |||
| Angiotensin-converting enzyme inhibitors | 7 | 0 | |
| Angiotensin receptor blockers | 4 | 0 | |
| β receptor blockers | 8 | 0 | |
| Statins | 4 | 0 | |
| Aspirin | 2 | 0 | |
| Amiodarone | 10 | 0 | |
| Dimethyl biguanide | 6 | 0 | |
| Oral anticoagulation therapy | 13 | 0 | 0 |
Data are presented as mean ± standard deviation or median (interquartile range), as appropriate.